Subject
Editions published in Pharmacogenetics and Genomics 200
Too many entities requested (2362). Only 200 are displayed.
-
Genome-wide association study of paliperidone efficacy
-
Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation
-
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
-
Dietary intake alters gene expression in colon tissue: possible underlying mechanism for the influence of diet on disease
-
PharmGKB summary: very important pharmacogene information for RYR1
-
Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics
-
PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics
-
Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics
-
Impact of the canine double-deletion β1 adrenoreceptor polymorphisms on protein structure and heart rate response to atenolol, a β1-selective β-blocker.
-
Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data
-
Pharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry: assessment using data simulation.
-
PharmGKB summary: very important pharmacogene information for UGT1A1
-
Comparison of delivery strategies for pharmacogenetic testing services
-
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
-
NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia
-
Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine
-
Deciphering ADME genetic data using an automated haplotype approach
-
Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model
-
PharmGKB summary: very important pharmacogene information for SLC22A1
-
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
-
PharmGKB summary: abacavir pathway
-
Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses
-
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics
-
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping
-
PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor
-
ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse
-
Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
-
PharmGKB summary: Diuretics pathway, pharmacodynamics
-
PharmGKB summary: tamoxifen pathway, pharmacokinetics
-
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6
-
A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants
-
Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis
Subject - wd:Q10534561